Chamath Palihapitiya · Aug 23, 09:29 PM UTC
Bitcoin’s Best Week Since 2024
Historical operation · Retained
“On August 19, Moderna and Merck reported that their personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy built using the same mRNA technology as Moderna’s COVID vaccine.”
Quoted source · Chamath Palihapitiya · 4 source segments
- [1] Chamath Palihapitiya
- [2] Chamath Palihapitiya
- [3] Chamath Palihapitiya
- [4] Chamath Palihapitiya
Model assessment
Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.
4 exact transcript citations